Augmentin Safety in Third Trimester
Augmentin (amoxicillin-clavulanate) can be safely used during the third trimester of pregnancy when clinically indicated, as it is FDA Pregnancy Category B with no evidence of fetal harm in animal studies or increased risk of major congenital malformations in human studies.
FDA Classification and Animal Data
The FDA labels Augmentin as Pregnancy Category B, meaning reproduction studies in pregnant rats and mice at doses up to 1,200 mg/kg/day (4.9 and 2.8 times the maximum adult human dose based on body surface area) revealed no evidence of harm to the fetus 1. However, the label appropriately notes that animal studies are not always predictive of human response, so the drug should be used during pregnancy only if clearly needed 1.
Human Safety Data
Multiple large-scale human studies support the safety profile:
A population-based cohort study of 101,615 pregnancies found no significant association between first-trimester exposure to amoxicillin or amoxicillin-clavulanate and major malformations (adjusted relative risk 1.09,95% CI 0.98-1.20), with no dose-response relationship identified 2
A case-control study of 6,935 cases and 10,238 controls showed no increased risk of congenital abnormalities with augmentin treatment (crude OR 1.4,95% CI 0.9-2.0) 3
A prospective controlled study of 191 exposed pregnancies found malformation rates of 1.9% in the augmentin group versus 3% in controls (P = 0.49), within expected baseline risk 4
Critical Third Trimester Consideration: Necrotizing Enterocolitis
The one specific concern for late pregnancy use relates to premature rupture of membranes (PROM). A 2001 clinical trial reported an increased risk of necrotizing enterocolitis in neonates whose mothers received prophylactic augmentin for preterm PROM 1. However, this finding has not been confirmed in three subsequent studies published between 2001 and 2008, and the original study had methodological limitations 5.
Current evidence does not support an increased risk of necrotizing enterocolitis with augmentin use in late pregnancy 5. The concern was specific to the prophylactic use in preterm PROM, not therapeutic use for active infections.
Labor and Delivery Considerations
The FDA label notes that:
- Oral ampicillin-class antibiotics are generally poorly absorbed during labor 1
- Effects on uterine contractions, labor duration, or need for obstetrical intervention are unknown in humans 1
- Ampicillin-class antibiotics are excreted in breast milk, requiring caution in nursing mothers 1
Clinical Recommendation Algorithm
Use augmentin in the third trimester when:
- There is a documented bacterial infection requiring treatment
- The benefits of treating the infection outweigh theoretical risks
- Augmentin is the appropriate antibiotic choice based on susceptibility patterns
Exercise additional caution in:
- Preterm premature rupture of membranes (consider alternative antibiotics if equally effective options exist)
- Immediately before delivery (though not contraindicated)
Monitor for:
- Standard antibiotic side effects (gastrointestinal symptoms are most common)
- Neonatal outcomes if used near delivery, particularly in preterm situations
Bottom Line
Augmentin can be prescribed at any stage of pregnancy, including the third trimester and just before delivery, when clinically indicated for bacterial infections 5. The evidence base from both animal studies and large human cohorts supports its safety profile, with the single caveat being judicious use in preterm PROM where alternative antibiotics should be considered if equally effective.